{"product_id":"legendbiotech-swot-analysis","title":"Legend Biotech SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eLegend Biotech's SWOT reveals powerful clinical momentum and niche biotech positioning, balanced by regulatory and commercialization risks. Our concise preview highlights key strengths, vulnerabilities, opportunities, and threats to inform your view. Want the full story behind the company’s strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain a professionally written, editable report tailored for investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading CAR-T in multiple myeloma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech co-developed cilta-cel (Carvykti), a best-in-class BCMA CAR-T showing ORR ~97% and CR ~67% with median DOR reported ~34.9 months in updated CARTITUDE data, with real-world series mirroring deep, durable responses. Robust clinical and emerging real-world outcomes have driven strong physician uptake and improving payer coverage, supporting reported 2024 global sales of roughly $1.1 billion. This leadership enables line extensions and trials in earlier lines to expand addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnership with a global pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe strategic collaboration with Janssen (Johnson \u0026amp; Johnson) de-risks development, commercialization, and market access by combining Legend Biotech science with Janssen’s global commercial footprint (60+ countries) and regulatory depth; FDA approval of cilta-cel (Carvykti) in November 2022 underscores that validation. Joint execution supplies capital, accelerates label expansion and geographic rollout, and boosts credibility with payers, clinicians, and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated cell therapy manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntegrated end-to-end capabilities in vector production and cell processing give Legend Biotech tight control over scale-up and supply for its CAR-T franchise (Carvykti approved by FDA in 2022), enhancing reliability with Janssen collaboration. Process know-how reduces batch variability and supports GMP compliance across sites. Recent capacity investments shorten bottlenecks and vein-to-vein time, creating an operational moat for the company (Nasdaq: LEGN).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified pipeline beyond hematologic cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech's pipeline extends beyond hematologic cancers into programs targeting multiple antigens and solid tumors, leveraging next‑generation constructs designed to improve persistence, safety and efficacy; the platform produced FDA‑approved cilta‑cel (Carvykti) in 2022, validating translational potential and commercial value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eMulti‑antigen\/solid‑tumor focus\u003c\/li\u003e\n\u003cli\u003eNext‑gen constructs for persistence, safety, efficacy\u003c\/li\u003e\n\u003cli\u003ePortfolio breadth spreads indication\/modality risk\u003c\/li\u003e\n\u003cli\u003eEnables lifecycle innovation around core CAR‑T platform\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong IP and regulatory momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech's patent portfolio protecting constructs, manufacturing and methods—backing the Janssen-partnered CAR-T ciltacabtagene autoleucel (Carvykti)—coupled with FDA approval in July 2022 and Breakthrough\/Orphan designations, accelerates development and market access; CARTITUDE-1 post-approval data showed a 97% overall response rate, creating clinical and commercial barriers to entry and guiding optimized use to sustain market leadership.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents: construct, manufacturing, methods\u003c\/li\u003e\n\u003cli\u003eRegulatory: FDA approval July 2022; Breakthrough\/Orphan designations\u003c\/li\u003e\n\u003cli\u003ePost-marketing: CARTITUDE-1 ORR 97%\u003c\/li\u003e\n\u003cli\u003ePartnership: Janssen collaboration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-efficacy BCMA CAR-T: ORR \u003cstrong\u003e97%\u003c\/strong\u003e, CR ~67%, DOR 34.9 mo, 2024 $1.1B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech’s cilta‑cel shows ORR 97%, CR ~67% and median DOR ~34.9 months; 2024 global sales ~ $1.1B with strong real‑world durability driving uptake and payer coverage. Janssen partnership (60+ countries) de‑risks commercialization and scale; in‑house vector\/manufacturing shortens vein‑to‑vein and secures supply.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eORR\u003c\/td\u003e\n\u003ctd\u003e97%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCR\u003c\/td\u003e\n\u003ctd\u003e~67%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian DOR\u003c\/td\u003e\n\u003ctd\u003e34.9 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Sales\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner reach\u003c\/td\u003e\n\u003ctd\u003e60+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Legend Biotech’s internal strengths and weaknesses and external opportunities and threats, highlighting competitive position, growth drivers like CAR‑T assets and partnerships, operational gaps, and regulatory and market risks shaping its future.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear, high-level SWOT summary of Legend Biotech to quickly align strategy and relieve analysis bottlenecks for executives and teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue concentration on a single asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDependence on Carvykti, approved in 2022, leaves Legend highly exposed: any safety signal, supply disruption, or rival CAR-T entry could sharply dent sales. Carvykti remains the companys primary revenue driver, constituting the majority of 2024 revenue as diversification programs progress but will take years to meaningfully reduce concentration risk, elevating earnings volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh COGS and complex logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersonalized autologous manufacturing for Legend's Carvykti remains costly and time-consuming, with per-patient manufacturing and logistics often exceeding $100,000 while US list price is $465,000. Cold-chain, scheduling and limited manufacturing capacity constrain throughput and raise failure\/waste risk. These factors push cell-therapy gross margins well below typical small-molecule margins (small-molecule COGS often \u0026lt;20%), complicating rapid global scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSafety management requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSafety management for BCMA CAR-Ts requires REMS-like controls and specialized centers; CRS occurs in up to 95% of pivotal cilta-cel patients and neurotoxicity\/ICANS in roughly 20–25%, with grade ≥3 events reported in about 5–10%. Intensive monitoring and inpatient stays raise treatment burden and costs, often adding thousands of dollars per patient. Serious events limit eligibility and physician comfort and can prompt regulatory scrutiny or label constraints.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensity and cash burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBuilding capacity, running pivotal trials and funding global CAR-T launches require substantial capital—often tens to hundreds of millions per manufacturing site and trial cohort—pressuring cash reserves. Approval delays or slower-than-expected uptake can extend the cash runway and force equity raises, diluting shareholders. Market downturns since 2022 have tightened biotech financing, increasing cost of capital and constraining access to funds.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh capital intensity\u003c\/li\u003e\n\u003cli\u003eCash burn risk from trial\/launch delays\u003c\/li\u003e\n\u003cli\u003eDependence on external financing → dilution\u003c\/li\u003e\n\u003cli\u003eMarket cycles limit capital access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited standalone commercial footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReliance on Janssen for Carvykti commercialization limits Legend Biotech’s direct market influence and leaves core market access functions with its partner, constraining Legend’s bargaining power with payers and providers. In-house capabilities for broad market access and real-world data generation remain smaller than big pharma peers, slowing tactical responses to competitive dynamics and pricing pressure. This dependence reduces negotiating leverage and speed of commercial adjustments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-led commercialization — Janssen handles global launch\u003c\/li\u003e\n\u003cli\u003eSmaller real-world evidence capacity vs big pharma\u003c\/li\u003e\n\u003cli\u003eLimited direct payer\/provider negotiating leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle CAR-T reliance, prohibitive manufacturing costs and severe toxicity threaten growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDependence on Carvykti (primary 2024 revenue driver) concentrates commercial risk; any safety, supply or competitor CAR-T could sharply cut sales. Autologous manufacturing\/ logistics often exceed $100,000 per patient versus US list price $465,000, limiting margins and scale. High toxicity (CRS up to 95%; neurotoxicity 20–25%; grade ≥3 ~5–10%) and capital needs (tens–hundreds $m\/site) constrain uptake and cash runway.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS list price\u003c\/td\u003e\n\u003ctd\u003e$465,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-patient manufacturing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRS incidence\u003c\/td\u003e\n\u003ctd\u003eup to 95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurotoxicity\u003c\/td\u003e\n\u003ctd\u003e20–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrade ≥3 events\u003c\/td\u003e\n\u003ctd\u003e~5–10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite capex\u003c\/td\u003e\n\u003ctd\u003etens–hundreds $m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eLegend Biotech SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Legend Biotech SWOT Analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report; buying unlocks the complete, editable version with in-depth strengths, weaknesses, opportunities and threats. Access is immediate after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164298260857,"sku":"legendbiotech-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/legendbiotech-swot-analysis.png?v=1762730228","url":"https:\/\/portersfiveforce.com\/products\/legendbiotech-swot-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}